Jacob Gottlieb, MD, CFA, PRMIA, is a healthcare industry focused hedge fund manager. He graduated magna cum laude from Brown University, earning an economics degree, and attended New York University Medical School to attain his medical degree. He completed his internship in internal medicine before deciding he would rather enter the financial industry and use his medical background to invest in small-cap and mid-cap healthcare firms.
After earning his Chartered Financial Analyst designation in 2001, he became an analyst at the hedge fund firm Sanford C. Bernstein & Co., LLC. He worked at Merlin next and then co-founded another healthcare-focused hedge fund firm, Balyasny Asset Management, L.P., before founding his first financial firm Visium Asset Management.
When Jacob Gottlieb’s Visium was at its height it managed $8 billion in assets and had offices in New York City, San Francisco, and London. His company had to be shut down, though, as an insider trading scandal involving it exploded into the news. He had his name cleared of any legal wrongdoing but as he was the last executive standing he made the decision to shut down operations and return the investor’s money.
He is now back applying his investing acumen at his latest firm, Altium Capital. His first move was to take a stake of 5.61% in Oramed Pharmaceuticals who developed a highly innovative oral solution for diabetes that can be used instead of diabetics jabbing themselves with a needle.
Jacob Gottlieb has also invested in two other promising healthcare firms, Amarin and Oragenics. The first of these is addressing cardiovascular health while the latter one is involved in Replacement Therapy. This form of therapy is predicated upon replacing harmful bacteria that cause infectious disease with beneficial bacteria that actually enhance health. It’s pretty cutting-edge stuff and Jacob Gottlieb sees a lot of promise in it.